VolitionRX (VNRX) PT Set at $5.00 by Oppenheimer

Oppenheimer set a $5.00 price target on VolitionRX (NYSEAMERICAN:VNRX) in a research report report published on Friday. The firm currently has a buy rating on the medical research company’s stock.

NYSEAMERICAN:VNRX traded up $0.03 on Friday, hitting $2.73. The stock had a trading volume of 15,304 shares, compared to its average volume of 108,530. VolitionRX has a 52 week low of $1.44 and a 52 week high of $4.00.

VolitionRX (NYSEAMERICAN:VNRX) last announced its quarterly earnings results on Wednesday, November 7th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14).

In other news, Director Guy Archibald Innes purchased 50,000 shares of the business’s stock in a transaction on Thursday, August 16th. The shares were acquired at an average price of $2.00 per share, for a total transaction of $100,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

An institutional investor recently bought a new position in VolitionRX stock. Leisure Capital Management acquired a new position in VolitionRX Ltd (NYSEAMERICAN:VNRX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 72,479 shares of the medical research company’s stock, valued at approximately $188,000. Leisure Capital Management owned about 0.21% of VolitionRX as of its most recent SEC filing.

VolitionRX Company Profile

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Featured Article: Investing in Growth Stocks

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply